

Clinical Trial Protocol

Iranian Registry of Clinical Trials

07 Jul 2026

Comparison of the effect of salbutamol and inhaled epinephrine and 5% hypertonic saline on reducing the severity of symptoms and duration of hospitalization of infants with bronchiolitis

Protocol summary

Study aim

Determining the effect of 5% salbutamol, epinephrine and saline hypertonic saline on the treatment of infants with bronchiolitis

Design

Clinical trial with three intervention groups, with parallel groups, double-blind, randomized, phase 3 on 45 infants. The Randomizer Software will be used for randomization.

Settings and conduct

Eligible infants after randomization were divided into three groups and the first group was 2.5 mg / kg body weight of salbutamol every 4 hours via nebulizer and the second group epinephrine via nebulizer at 0.5 mg / kg, and the third group of 5% NaCl at 3 cc in 0, 30 and 60 minutes

Participants/Inclusion and exclusion criteria

In this study, infants from 2 months to 24 months referred to Taleghani Educational and Medical Center who have symptoms of bronchiolitis and a respiratory score of 4 or higher based on Pediatric respiratory severity will be included. In contrast to infants born prematurely and hospitalized during the first two months of life, people with a history of chronic cardiopulmonary disease or hypersensitivity and drug reactions to salbutamol, epinephrine, and hypertonic saline, or those before Hospitalized for bronchodilators and corticosteroids will not be included in the study

Intervention groups

In this study, there are three intervention groups: group A users of inhaled salbutamol, group B users of inhaled epinephrine and group C users of inhaled hypertonic saline solution.

Main outcome variables

Severity of clinical symptoms including respiratory distress, skin color, general mood, number of breaths, body temperature, and auscultation by physician

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20201101049210N1**

Registration date: **2020-11-22, 1399/09/02**

Registration timing: **prospective**

Last update: **2020-11-22, 1399/09/02**

Update count: **0**

Registration date

2020-11-22, 1399/09/02

Registrant information

Name

Lobat Shahkar

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3222 7720

Email address

lobatshahkar@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-11-25, 1399/09/05

Expected recruitment end date

2021-03-25, 1400/01/05

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effect of salbutamol and inhaled epinephrine and 5% hypertonic saline on reducing the severity of symptoms and duration of hospitalization of infants with bronchiolitis

Public title

Comparing the effects of nebulized salbutamol epinephrine and 5 hypertonic saline on lowering theseverity of symptoms in infant

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

pediatric respiratory severity score \geq 4 history of lower respiratory tract infections wheezing,cough,cyanosis,spo₂<90, fever age 2-24 month

Exclusion criteria:

drug reaction to salbutamol or epinephrine or hypertonic salin history of chronic cardiopulmonary disease preterm labor history of admision in age 0-2 month history of treatment with bronchodilator agents history of corticosteroid administration

Age

From **2 months** old to **24 months** old

Gender

Both

Phase

3

Groups that have been masked

- Care provider
- Outcome assessor

Sample size

Target sample size: **45**

Randomization (investigator's opinion)

Randomized

Randomization description

After obtaining informed consent from the parents of eligible infants, their allocation to each of the three groups receiving salbutamol inhaler (a), inhaler epinephrine (b) and saline recipient Inhalation hypertension (c) will occur randomly. For this purpose, the Randomizer Software will be used. based on the software output, the entrance sequence of participants will be written in advance by one of the members of the research team on cards with the letters a, b, and c and will be placed in sealed and numbered envelopes. Once the eligibility of the infants is determined based on the inclusion and exclusion criteria, the numbers listed on the envelope will be determined in each of the groups. For example, for the first infant, envelope number 1 is opened and according to the letter in that group, the intervention will be specified and the desired intervention will be applied. Due to the fact that the sequence of entry of individuals by a person other than the person responsible for the intervention will be specified and placed in sealed envelopes, the process of entry of infants into each of the intervention groups will remain secret until the envelopes are opened.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, the infant's parents, the person responsible for the intervention, and the person evaluating the outcome of the intervention will be kept unaware of how people are placed in the groups. In this way, the process of entering the groups will be determined in advance by one of the members of the research team and will be placed in numbered envelopes in the package. For this reason, when the infant is found to be eligible according to the inclusion criteria, the person responsible for the intervention (first physician) and the parents will be unaware of the type of intervention received (three intervention groups). After obtaining the consent of one of the envelopes, the numbers will be opened in order, and only at this stage it will be determined in which group the child will be placed. It should be noted that in this study, infants will be visited by two independent physicians. The first physician after assigning the child to the groups to apply the intervention and the second physician 24 and 48 hours after the intervention to evaluate the response to treatment. For this reason, both the intervention practitioner and the physician are responsible for evaluating the outcome of the intervention (response to treatment) and are unaware of the allocation.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Golestan University of Medical Sciences

Street address

Hircan Blvd., at the beginning of Shast Kola Road, Falsafi Educational Campus of Golestan University of Medical Sciences

City

Gorgan

Province

Golestan

Postal code

4934174515

Approval date

2020-10-04, 1399/07/13

Ethics committee reference number

IR.GOUMS.REC.1399.222

Health conditions studied

1

Description of health condition studied

Acute bronchiolitis

ICD-10 code

J21

ICD-10 code description

Acute bronchiolitis

Primary outcomes

1

Description

Primary Outcome: Clinical signs including severity of respiratory distress, wheezing, skin color, general mood, respiratory rate, body temperature, and lung murmur

Timepoint

Before the intervention and 24 and 48 hours after the intervention

Method of measurement

Based on the score obtained from the pediatric respiratory severity score and observation

Secondary outcomes

1

Description

The length of hospital stay is the number of days a patient receives medication, parenteral fluid, and oxygen for bronchiolitis

Timepoint

Once at the end of the treatment period

Method of measurement

Count the days the patient receives medication, parenteral fluid, and oxygen for bronchiolitis

Intervention groups

1

Description

Recipients of inhaled salbutamol. Nebulizer treated with salbutamol 2.5 mg / kg every 4 hours via nebulizer and 48 to 24 hours after hospitalization

Category

Treatment - Drugs

2

Description

Intervention group: Recipients of inhaled epinephrine via nebulizer at 0.5 mg / kg and 48 to 24 hours after hospitalization

Category

Treatment - Drugs

3

Description

Intervention group: Recipients of inhaled hypertonic

saline (5% NaCl) at 3 cc at 0, 30 and 60 minutes

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Taleghani Medical Educational Center

Full name of responsible person

Lobat Shahkar

Street address

Azadi St., Janbazan Boulevard, In Front Of Janbaz 22

City

Gorgan

Province

Golestan

Postal code

4916668197

Phone

+98 17 3222 7720

Fax

+98 17 3225 6440

Email

Taleghani@goums.ac.ir

Web page address

http://goums.ac.ir/index.php?slc_lang=fa&sid=31

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Gorgan University of Medical Sciences

Full name of responsible person

Mohamadreza Honarvar

Street address

Hyrkan Boulevard, at The Beginning of ShastKola Road, Falsafi Educational Campus, Deputy of Research and Technology

City

Gorgan

Province

Golestan

Postal code

4934174515

Phone

+98 17 3245 1660

Fax

+98 17 3245 1657

Email

Honarvar@goums.ac.ir

Web page address

http://goums.ac.ir/index.php?slc_lang=fa&sid=12

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Gorgan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Taleghani Hospital Janbazan St

City

Gorgan

Province

Golestan

Postal code

4916668197

Phone

+98 17 3222 7720

Email

Lobatshahkar@yahoo.com

Person responsible for general inquiries**Contact****Name of organization / entity**

Gorgan University of Medical Sciences

Full name of responsible person

Seyed Ali Mosavikhosravi

Position

Student

Latest degree

Medical doctor

Other areas of specialty/work

Pediatrics

Street address

Taleghani Medical Educational Center, Janbazan Ave

City

Gorgan

Province

Golestan

Postal code

4918668197

Phone

+98 17 3224 7622

Email

dr.ali.m363@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Gorgan University of Medical Sciences

Full name of responsible person

Lobat Shahkar

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address**Person responsible for updating data****Contact****Name of organization / entity**

Gorgan University of Medical Sciences

Full name of responsible person

Seyed Ali Mosavikhosravi

Position

student

Latest degree

Medical doctor

Other areas of specialty/work

Pediatrics

Street address

Taleghani Medical Educational Center, Janbazan Ave.

City

Gorgan

Province

Golestan

Postal code

4918668197

Phone

+98 17 3224 7324

Email

dr.ali.m363@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available